Re: For what it’s worth

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

tada

Rank: President [?]

Points: 7750 [?]

Votes: 40 Score: 3.4 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: For what it’s worth

in response to

Re: For what it’s worth

KOO-KOO2

posted on Jul 19, 2023 05:11PM

KK2 - If memory serves correctly this trial is being done by MSK and paid for by the National Cancer Institute (NIH). Zenith Epigenetics Ltd does not have the funds to do any trials on their own, however the NUT Midline may push that narrative.

There doesn't appear to be anywhere in any descriptors for who is funding any part of the trial.